Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis



[
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
[og_img]
https://www.investing.com/news/press-releases/immix-biopharma-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-nxc201-stericallyoptimized-cart-for-relapsedrefractory-al-amyloidosis-93CH-3859522


Investing.com

Latest articles

spot_imgspot_img

Related articles

spot_imgspot_img